Leckie J, Yokota T
Genes (Basel). 2025; 16(2).
PMID: 40004514
PMC: 11855077.
DOI: 10.3390/genes16020185.
Jirakittiwut N, Sathianpitayakul P, Santanirand P, Akeda Y, Vilaivan T, Ratthawongjirakul P
Sci Rep. 2025; 15(1):2603.
PMID: 39837979
PMC: 11751166.
DOI: 10.1038/s41598-025-86691-8.
Zhong Y, Wilkinson-White L, Zhang E, Mohanty B, Zhang B, McRae M
PLoS One. 2024; 19(9):e0310565.
PMID: 39283902
PMC: 11404819.
DOI: 10.1371/journal.pone.0310565.
Zhu J, Liang Z, Yao H, Wu Z
Antibiotics (Basel). 2024; 13(8).
PMID: 39200025
PMC: 11350675.
DOI: 10.3390/antibiotics13080725.
Westerlund K, Oroujeni M, Gestin M, Clinton J, Hani Rosly A, Tano H
ACS Pharmacol Transl Sci. 2024; 7(5):1595-1611.
PMID: 38751640
PMC: 11091976.
DOI: 10.1021/acsptsci.4c00106.
Subtractive modification of bacterial consortium using antisense peptide nucleic acids.
Hizume T, Sato Y, Iwaki H, Honda K, Okano K
Front Microbiol. 2024; 14:1321428.
PMID: 38260881
PMC: 10800778.
DOI: 10.3389/fmicb.2023.1321428.
Advances in Nucleic Acid Research: Exploring the Potential of Oligonucleotides for Therapeutic Applications and Biological Studies.
Moccia M, Pascucci B, Saviano M, Cerasa M, Terzidis M, Chatgilialoglu C
Int J Mol Sci. 2024; 25(1).
PMID: 38203317
PMC: 10778772.
DOI: 10.3390/ijms25010146.
Antitumor efficacy of a sequence-specific DNA-targeted γPNA-based c-Myc inhibitor.
Malik S, Pradeep S, Kumar V, Xiao Y, Deng Y, Fan R
Cell Rep Med. 2024; 5(1):101354.
PMID: 38183981
PMC: 10829792.
DOI: 10.1016/j.xcrm.2023.101354.
Dynamic and static control of the off-target interactions of antisense oligonucleotides using toehold chemistry.
Terada C, Oh K, Tsubaki R, Chan B, Aibara N, Ohyama K
Nat Commun. 2023; 14(1):7972.
PMID: 38042877
PMC: 10693639.
DOI: 10.1038/s41467-023-43714-0.
Supramolecular Nucleic Acid-Based Organosilica Nanoparticles Responsive to Physical and Biological Inputs.
Picchetti P, Volpi S, Sancho-Albero M, Rossetti M, Dore M, Trinh T
J Am Chem Soc. 2023; 145(42):22903-22912.
PMID: 37844092
PMC: 10603779.
DOI: 10.1021/jacs.3c04345.
Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide.
Haque U, Yokota T
Cells. 2023; 12(19).
PMID: 37830609
PMC: 10572411.
DOI: 10.3390/cells12192395.
Pyrenebutyrate Enhances the Antibacterial Effect of Peptide-Coupled Antisense Peptide Nucleic Acids in .
Abt C, Gerlach L, Bull J, Jacob A, Kreikemeyer B, Patenge N
Microorganisms. 2023; 11(9).
PMID: 37763975
PMC: 10537354.
DOI: 10.3390/microorganisms11092131.
Responsive Nucleic Acid-Based Organosilica Nanoparticles.
Picchetti P, Volpi S, Rossetti M, Dore M, Trinh T, Biedermann F
J Am Chem Soc. 2023; 145(42):22896-22902.
PMID: 37734737
PMC: 10603775.
DOI: 10.1021/jacs.3c00393.
Identifying Antisense Oligonucleotides to Disrupt Small RNA Regulated Antibiotic Resistance via a Cell-Free Transcription-Translation Platform.
Tsai M, Zambrano R, Susas J, Silva L, Takahashi M
ACS Synth Biol. 2023; 12(8):2245-2251.
PMID: 37540186
PMC: 10443041.
DOI: 10.1021/acssynbio.3c00245.
The Current Progress of Tetrahedral DNA Nanostructure for Antibacterial Application and Bone Tissue Regeneration.
Hong S, Jiang W, Ding Q, Lin K, Zhao C, Wang X
Int J Nanomedicine. 2023; 18:3761-3780.
PMID: 37457798
PMC: 10348378.
DOI: 10.2147/IJN.S403882.
Identifying antisense oligonucleotides to disrupt small RNA regulated antibiotic resistance via a cell-free transcription-translation platform.
Tsai M, Zambrano R, Susas J, Silva L, Takahashi M
bioRxiv. 2023; .
PMID: 37131760
PMC: 10153260.
DOI: 10.1101/2023.04.19.537543.
Current Status of Oligonucleotide-Based Protein Degraders.
Shih P, Naganuma M, Demizu Y, Naito M
Pharmaceutics. 2023; 15(3).
PMID: 36986626
PMC: 10055846.
DOI: 10.3390/pharmaceutics15030765.
Nucleic acid nanostructures for applications: The influence of morphology on biological fate.
Langlois N, Ma K, Clark H
Appl Phys Rev. 2023; 10(1):011304.
PMID: 36874908
PMC: 9869343.
DOI: 10.1063/5.0121820.
Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.
Wang Y, Malik S, Suh H, Xiao Y, Deng Y, Fan R
Sci Adv. 2023; 9(6):eabq7459.
PMID: 36753549
PMC: 9908025.
DOI: 10.1126/sciadv.abq7459.
Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics.
Pradeep S, Malik S, Slack F, Bahal R
RNA. 2023; 29(4):434-445.
PMID: 36653113
PMC: 10019372.
DOI: 10.1261/rna.079498.122.